Alameda, CA (USA) – September 6, 2024 – PTM BIO, a leading provider of proteomics services and research products, announces the opening of a new proteomics laboratory in Alameda, CA. The facility, which became fully operational on September 1, 2024, boosts PTM BIO’s capacity to meet the demand for high-quality proteomics data and services from its growing client base.
“While PTM BIO has been serving customers worldwide, establishing a dedicated proteomics laboratory in Alameda strengthens our presence in the United States and enhances our ability to support the research community across North America,” said Dr. Zhongyi Cheng, Chief Executive Officer of PTM BIO. "The opening of this facility also marks a major step forward in our mission to advance the field of proteomics. With the integration of the Orbitrap™ Astral™ Mass Spectrometer, offering increased throughput, deeper coverage, and greater sensitivity, we aim to provide our clients with the most accurate and precise proteomics data available.”
This expansion reflects PTM BIO’s ongoing growth and solidifies its position as a leader in the proteomics industry. The company remains dedicated to supporting biomedical and pharmaceutical research through its PTM reagents, mass spectrometry expertise, and bioinformatics tools.
About PTM BIO
Founded in 2010, PTM BIO is a leading innovator in proteomics and epigenetics. The company excels in integrating proprietary PTM reagents with advanced mass spectrometry and bioinformatics tools to deliver comprehensive proteomics solutions. PTM BIO is well-positioned to apply state-of-the-art proteomics strategies to drive medical research and to enhance therapeutic outcomes.
